Study Evaluating The Potential Effect Of Rifampin On The Pharmacokinetics Of Neratinib

Puma Biotechnology, Inc.24 enrolled

Overview

The purpose of this study is to examine whether co-administration of rifampin with neratinib has an effect on the pharmacokinetics (how the body absorbs, distributes, metabolizes and/or excretes) of neratinib.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Healthy Subjects

Interventions

NeratinibDRUG

HKI-272

Eligibility

Sex: ALLMin age: 18 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion criteria: * Healthy men or women (of non childbearing potential) * Ages 18 to 50 years old.

Locations (1)

Unnamed facility

Miami, Florida, United States

Outcomes

Primary Outcomes

Pharmacokinetics (plasma blood concentrations)

Time frame: 4 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.